Professor Chris Molloy begins Chief Executive Officer role

The UK BioIndustry Association (BIA) is delighted to announce Professor Chris Molloy has taken up his role as Chief Executive Officer.

Chris has joined BIA from the Medicines Discovery Catapult (MDC), where was is the founding CEO, leading collaboration across academia, industry, the NHS and private capital to accelerate innovation for patients in the UK and beyond.

He is a Trustee of the Institute of Cancer Research and Chair of the Industry Advisory Boards for the Greater Manchester Biomedical Research Centre and Health Innovation Manchester. During the COVID‑19 pandemic, Chris established and led the UK’s Lighthouse Laboratories, delivering the largest diagnostics programme in the country, and chaired the UK consortium responsible for the manufacture and scale‑up of lateral flow testing.

With more than 30 years’ experience across the life sciences sector, Chris brings deep expertise spanning biopharma, diagnostics, venture‑backed companies, talent development and data and informatics.

Chris said:

Today marks my first day as CEO of BIA. It’s an honour to represent and serve this pioneering community of biotech entrepreneurs, investors and enabling services companies. From translation to finance and from trials to regulation, the UK enables great biotech companies to become deeply rooted and grow, benefitting patients, pensioners and the wider economy.

BIA is a national and international champion for this community and a trusted advisor to the policymakers and public bodies who enable the environment that nurtures it. Thanks to the Board, our new Chair Shaun Grady and outgoing Chair Dan Mahony, as well as the wider BIA team, for the opportunity to serve.